Early Life
Sun Piaoyang was born in Lianyungang, China, in 1958. From a young age, he showed exceptional academic talent. He earned a bachelor's degree from China Pharmaceutical University and a doctorate from Nanjing University. Education played a crucial role in his career.
Rise to Success
Sun's career began at the state-run Lianyungang Pharmaceutical Factory. He became the head of Jiangsu Hengrui Medicine at age 32. Under his leadership, the company shifted its focus to research and development. In 2000, Hengrui went public on the Shanghai Stock Exchange. Sun spearheaded the development of innovative drugs, including Apatinib for late-stage gastric cancer. In 2014, the FDA approved its injectable drug oxaliplatin.
Key Business Strategies
Sun Piaoyang's business philosophy centers on long-term innovation and investment in research and development. He invested heavily in two major research centers in Lianyungang and Shanghai. He prioritized the development of anti-tumor drugs, cardiovascular drugs, and surgical medications. Sun also focused on international expansion and strategic partnerships, including obtaining FDA approvals.
Philanthropy
Sun has shown a commitment to social welfare. Jiangsu Hengrui Medicine has invested in poverty alleviation and supported various cultural and economic activities. The company has also invested tens of millions of yuan in social welfare since 2000.